Granules India Limited announced its unaudited financial results for the third quarter and nine months ended December 31, 2025. The company reported a total revenue from operations of ₹8,953.18 crore for the quarter, a slight increase from the previous quarter. Profit after tax for the quarter stood at ₹1,115.82 crore. For the nine-month period ended December 31, 2025, Granules India reported a total revenue from operations of ₹25,971.39 crore and a profit after tax of ₹3,016.80 crore. The company also disclosed an exceptional item for the nine months, amounting to ₹121.60 million (₹12.16 crore) in transaction costs related to the acquisition of Senn Chemicals AG. The consolidated financial results for the same period showed a total revenue from operations of ₹13,879.40 crore for the quarter and ₹39,065.89 crore for the nine months. Consolidated profit after tax for the quarter was ₹1,502.11 crore, and for the nine months, it was ₹3,934.53 crore. The consolidated results also included exceptional items amounting to ₹259.11 million (₹25.91 crore) for the nine months, related to acquisition costs and litigation settlements. The company highlighted the acquisition of M/s Granules Pharmaceuticals GmbH in Germany on November 20, 2025, and the incorporation of a new subsidiary, Granules Pharmaceuticals Canada, Inc., in Canada on November 26, 2025. Additionally, the Board of Directors and shareholders approved capital-raising measures, including the issuance of convertible warrants aggregating up to ₹14,625 crore and equity shares aggregating up to ₹3,000 crore, subject to regulatory approvals.
